中性粒细胞淋巴细胞比值对急性ST段抬高型心肌梗死再灌注损伤的预测价值被引量：3

Value of neutrophil to lymphocyte ratio in predicting occurrence of myocardial ischemia-reperfusion injury in patients with ST-segment elevation myocardial infarction

下载PDF

导出

摘要目的探讨中性粒细胞/淋巴细胞比值(NLR)对急性ST段抬高型心肌梗死(STEMI)患者经皮冠状动脉介入治疗(PCI)后发生缺血再灌注损伤(MIRI)的预测价值。方法入选急性ST段抬高型心肌梗死患者118例,入院后即刻抽静脉血查血常规,按中性粒细胞/淋巴细胞比值的中位数将患者分为低NLR组和高NLR组,对两组MIRI发生率进行比较。结果高NLR组MIRI发生率明显高于低NLR组,差异具有统计学意义(P<0.01)。多元逐步回归分析也显示NLR是MIRI的独立危险因素(P<0.01)。结论入院时中性粒细胞/淋巴细胞比值是急性ST段抬高性心肌梗死患者经皮冠状动脉介入治疗后发生缺血再灌注损伤的可靠预测指标。 Objective To investigate the relationship between the neutrophil to lymphocyte ratio（ NLR} and the myocardi- al ischemia-reperfusion injury（MIRI） of ST-segment elevation myocardial infarction（STEMI}. Methods A total of 118 pa- tients with STEMI whose blood routines were obtained at the admission were studied. All cases were divided into two groups ac- cording to the median of the neutrophil to lymphocyte ratio and the incidences of MIRI of the two groups were compared. Re- sults The incidence of MIRI was higher in the high NLR group （ P 〈 0.01 ）. The multivariate stepwise regression analysis showed that the neutrophil to lymphocyte ratio was the independent risk factor for MIRI （ P 〈 0.01 ）. Conclusion The nentro- phil to lymphocyte ratio is a reliable indicator which can predict the occurrence of MIRI.

作者邵旭武王岳松张先林董学滨王学忠章萍

机构地区安徽省马鞍山市人民医院心血管内科

出处《淮海医药》 CAS 2014年第5期421-423,共3页 Journal of Huaihai Medicine

关键词急性ST段抬高型心肌梗死中性粒细胞/淋巴细胞比值缺血再灌注损伤 ST-segment elevation myocardial infarction Neutrophil to lymphocyte ratio Myocardial ischemia-reperfusioninjury

分类号 R542.22 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献10

1Zazula AD, Pracoma-Neto D, Gomes AM, et al. An assessment of neutrophils/lymphocytes ratio in patients suspected of acute coronmy syndrome [ J]. Arq Bras Cardio1,2008,90 ( 1 ) : 31-36.
2罗义,吕磊,李广镰,皮耀球,曾冲,潘宜智,雷晓明,刘震.急性心肌梗死直接经皮冠状动脉介入术心肌缺血再灌注损伤的发病因素分析[J].中华心血管病杂志,2005,33(8):691-694. 被引量：17
3无.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2010,38(8):675-690. 被引量：1978
4Lassen JF, Btker HE, Terkelsen CJ. Timely and optimal treatment of patients with STEMI[ J]. Nat Rev Cardiol,2013,10( 1 ) :41-48.
5Weaver WD, Simes R J, Betriu A, et al. Comparison of primary coro- nary angioplasty and intravenous thrombolytic therapy for acute myo- cardial infarction: a quantitative review [ J ]. JAMA, 1997, 278 ( 23 ) :2093-2098.
6Arslan F, de Klein DP, Timmers L, et al. Bridging innate immunity and myocardial ischemia/reperfusion injury:the search for therapeu- tic targets[ J]. Curr Pharm Des,2008,14(12) :1205-1216.
7Mehta JH, Nichols WW, Mehta P. Neutrophil as potential partici-pants in acute myocardial ischemia: relevance to reperfusion [ J ]. J Am Coil Cardiol, 1988,11 ( 6 ) : 1309-1316.
8Chia S, Nagumey JT, Brown DF, et al. Association of leukocyte and neutrophil counts with infarct size, left ventricular function and out- comes after percutaneous coronary intervention for ST-elevation myo- cardial infarction[J]. Am J Cardiol,2009,103 (3) :333-337.
9Na/to Y, Fukma J, Tamai S, et al. B/phasic changes in Hypothalamo- pituitary-adrenal function during the early recovery period after major abdominal surgery [ J ]. J Clin Endocrinal Metab, 1991,73 ( 1 ) : 111 - 117.
10Kaya MG, Akpek M, Lam YY, et al. Prognostic value of neutrophil/ lymphocyte ratio in patients with ST-elevated myocardial infarction undergoing primary coronary intervention : a prospective, multicenter study [ J ]. Int J Cardio1,2013,168 (2) : 1154-1159.

二级参考文献19

1罗义,刘伊丽,陈瑗,黄晓波,查道刚,刘俭.过氧亚硝酸阴离子在心肌顿抑发生中的作用[J].中华内科杂志,2003,42(11):809-810. 被引量：3
2Collaborative Research Group of Reperfusion Therapy in Acute Myocardial Infarction.重组葡激酶与重组组织型纤溶酶原激活剂治疗急性心肌梗死的随机多中心临床试验[J].中华心血管病杂志,2007,35(8):691-696. 被引量：43
3Kalra DK, Zhu X, Ramchandani MK, et al. Increased myocardial gene expression of tumor necrosis factor-alpha and nitric oxide synthase-2: a potential mechanism for depressed myocardial function in hibernating myocardium in humans.Circulation, 2002, 105: 1537-1540.
4Iwakura K, Ito H, Kawano S, et al. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol, 2001, 38:472-477.
5Takahashi T, Anzai T, Yoshikawa T, et al. Absence of preinfarction angina is associated with a risk of no-reflow phenomenon after primary coronary angioplasty for a first anterior wall acute myocardial infarction.Int Cardiol J, 2000, 75:253-260.
6Tanaka A, Kawarabayashi T, Nishibori Y, et al. No-reflow phenomenon and lesion morphology in patients with acute myocardial infarction. Circulation, 2002,105:2148-2152.
7Galinanes M, Fowler AG.Role of clinical pathologies in myocardial injury following ischaemia and reperfusion.Cardiovasc Res,2004, 61:512-521.
8Widimsky P. Reperfusion damage or no-reflow damage in primary coronary interventions in acute myocardial infarction?Eur Heart J, 2002, 23:1076-1078.
9Weaver WD, Simes RJ, Betriu A et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997, 278: 2093-2098.
10Widimsky P, Groch L, Zelizko M, et al. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study.Eur Heart J, 2000, 21: 823-831.